FDA v. Alliance for Hippocratic Medicine

Summary

The Supreme Court held that the pro‑life doctors and medical associations lack Article III standing to challenge the FDA's 2016 and 2021 regulatory actions on mifepristone, reversing the Fifth Circuit and remanding for further proceedings. The Court explained that the plaintiffs failed to show a concrete injury, causation, and redressability, and rejected both individual and organizational standing theories.